Antibody-conjugated Mesenchymal Stromal Cells Drug Delivery System for Autoimmune Diseases Treatment (PRJCA047627)
Autoimmune diseases (AIDs), such as psoriasis and rheumatoid arthritis, are driven by immune dysfunction, leading to chronic inflammation and tissue damage.Mesenchymal stem stromal cells (MSCs) possess immunomodulatory and tissue repair properties but face limitations in homing efficiency while systemic infusion. Inspired by antibody-drug conjugates (ADC), this study developed an antibody-conjugated MSC-based drug delivery system (AcM-DDS), combining monoclonal antibody-conjugated MSCs  with liposome-encapsulated ROR?t inverse agonists. AcM-DDS targets cells, key drivers of AIDs, and precisely delivers ROR?t antagonists to suppress Th17-mediated inflammation.In mouse models of imiquimod-induced psoriasis and collagen-induced arthritis, AcM-DDS enhanced MSC homing to inflamed tissues, reduced Th17 activity, lowered pro-inflammatory cytokine production, and preserved cartilage and bone integrity. This platform offers a novel strategy for targeted immune modulation, providing a promising therapeutic approach for AIDs.